Edition:
United States

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

15.18USD
17 Aug 2018
Change (% chg)

$0.34 (+2.29%)
Prev Close
$14.84
Open
$14.76
Day's High
$15.35
Day's Low
$14.75
Volume
9,504
Avg. Vol
24,430
52-wk High
$28.95
52-wk Low
$13.00

Chart for

About

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing multi-asset pipeline of topical therapies that enhance the health, appearance of life of dermatology patients. It also advancing multiple product candidates derived from Topical by Design platform, all of which are... (more)

Overall

Beta: --
Market Cap(Mil.): $314.72
Shares Outstanding(Mil.): 20.73
Dividend: --
Yield (%): --

Financials

  SNNA.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -2.75 -- --
ROI: -55.24 2.89 12.63
ROE: -- 1.65 14.82

Sienna Biopharma sinks after acne treatment fails two trials

Sienna Biopharmaceuticals Inc said its lead experimental acne treatment failed to meet the main goals of two pivotal trials and that the chances of it clearing a third study appeared weaker, sending its shares tumbling 19 percent.

Jul 30 2018

UPDATE 2-Sienna Biopharma sinks after acne treatment fails two trials

* Shares hit record low (Adds details from conference call, updates share movement)

Jul 30 2018

CORRECTED-UPDATE 1-Sienna Biopharma sinks after acne drug fails two trials

July 30 Sienna Biopharmaceuticals Inc said on Monday two pivotal trials testing its lead experimental treatment for acne did not meet their main goals, sending its shares tumbling nearly 28 percent before the bell.

Jul 30 2018

Sienna Biopharmaceuticals' acne drug fails two trials

July 30 Sienna Biopharmaceuticals Inc said on Monday two pivotal trials testing its acne treatment did not meet their main goals of reducing inflammatory lesions on patients' skin.

Jul 30 2018

BRIEF-Sienna Biopharmaceuticals Reports Qtrly Loss Per Share $0.85

* SIENNA BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 14 2018

BRIEF-Sebacia Announces Favorable Ruling By U.S. Court Regarding Patent Proceedings With Sienna Biopharma

* SEBACIA - ANNOUNCES FAVORABLE RULING BY U.S. FEDERAL COURT REGARDING PATENT INTERFERENCE PROCEEDINGS WITH SIENNA BIOPHARMACEUTICALS INC

May 07 2018

BRIEF-Sienna Biopharmaceuticals Appoints John Smither As CFO

* SIENNA BIOPHARMACEUTICALS APPOINTS JOHN W. SMITHER AS CHIEF FINANCIAL OFFICER

Mar 21 2018

BRIEF-Sienna Biopharmaceuticals Qtrly Loss Per Share $0.56

* SIENNA BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 15 2018

BRIEF-Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-Of-Concept Trial Of Topical By Design JAK Inhibitor SNA-125 For Atopic Dermatitis

* SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PROOF-OF-CONCEPT TRIAL OF TOPICAL BY DESIGN™ JAK INHIBITOR SNA-125 FOR ATOPIC DERMATITIS

Mar 12 2018

Earnings vs. Estimates